3 Branded Medicine Maker, Group Holding Company and Consumerware Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, Godrej Industries and Cello World
- October 19, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
GSK Pharma Rs 2,566.10, P/E 40.20. Godrej Industries Rs 1,044.20, P/E 15.29. Cello World Rs 376.60, P/E 26.13. Closing prices of 14 Oct 2026.
Quick Answer
Branded medicine maker, group holding company and consumerware stocks with the clearest long-term roadmaps today include GSK Pharma in branded medicines and vaccines sold through a large doctor network, Godrej Industries in chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm and Cello World in consumerware, writing instruments and glassware sold under the Cello brand. FY26 revenue growth was 1.8% at GSK Pharma, 18.5% at Godrej Industries and 9.1% at Cello World. P/E stands at 40.20 for GSK Pharma (industry 37.59), 15.29 for Godrej Industries (industry 36.60) and 26.13 for Cello World (industry 45.71). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Branded medicine maker, group holding company and consumerware stocks give investors exposure to branded medicines, chemicals and kitchen goods. Volumes, pricing and margins decide how much of that demand turns into profit.
This list covers three branded medicine maker, group holding company and consumerware stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines sold through a large doctor network, Godrej Industries for chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm and Cello World for consumerware, writing instruments and glassware sold under the Cello brand. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Medicine Maker, Group Holding Company and Consumerware Stocks?
Branded medicine maker, group holding company and consumerware stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Branded Medicine Maker, Group Holding Company and Consumerware Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three branded medicine maker, group holding company and consumerware stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE |
|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals | 2,566.10 | 42,939 | 40.20 | 37.59 | 45.69% |
| Godrej Industries | 1,044.20 | 33,784 | 15.29 | 36.60 | 11.10% |
| Cello World | 376.60 | 8,476 | 26.13 | 45.71 | 12.27% |
Among healthcare and consumer stocks, GSK Pharma trades at a premium to the industry P/E, while Godrej Industries and Cello World trade at a discount.
Why Do Branded Medicine Maker, Group Holding Company and Consumerware Stocks Have a Strong Roadmap in India?
Branded medicine maker, group holding company and consumerware stocks have a strong roadmap in India because branded medicine demand, group business growth and household spending keep adding volumes for these firms. Three drivers stand out.
- Branded medicines: Doctors prescribe trusted brands and vaccines.
- Group businesses: Chemicals and group stakes add earnings.
- Household goods: Families buy consumerware and glassware.
GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap
GSK Pharma’s roadmap rests on branded medicines and vaccines sold through a large doctor network, with established brands supporting steady sales.
Revenue grew from Rs 3,353.80 crore in FY22 to Rs 3,967.03 crore in FY26, an 18.3% rise, and FY26 revenue was 1.8% higher than FY25. FY26 net profit rose 11.7% to Rs 1,035.98 crore. Over four years, net profit rose from Rs 380.77 crore in FY22 to Rs 1,035.98 crore. In Q1 FY27, revenue grew 15.7% to Rs 982.20 crore, and net profit rose 15.7% to Rs 237.18 crore. Operating margin was 38.60% in FY26.
Debt to equity is 0.01 and return on equity is 45.69%. FY26 operating cash flow was Rs 903.30 crore against capital expenditure of Rs 55.28 crore. GSK Pharma paid a dividend of Rs 57 per share for FY26, a yield of 2.25%. At a P/E of 40.20 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 40.20 is a modest premium to the industry P/E of 37.59, so the next quarters’ growth is the figure to follow.
Godrej Industries: Chemicals and Group Holdings Build the Next Leg
Godrej Industries’ roadmap rests on chemicals, along with stakes in listed group companies in real estate, consumer products and agri-business, and a finance arm, with its chemical business and holdings in other group companies widening the earnings base.
Revenue grew from Rs 15,064.67 crore in FY22 to Rs 25,980.60 crore in FY26, a 72.5% rise, and FY26 revenue was 18.5% higher than FY25. FY26 net profit rose 29.8% to Rs 2,411.91 crore. Over four years, net profit rose from Rs 992.43 crore in FY22 to Rs 2,411.91 crore. In Q1 FY27, revenue grew 11.2% to Rs 6,360.30 crore. Operating margin was 26.91% in FY26.
Return on equity is 11.10%. At a P/E of 15.29 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: The P/E of 15.29 against an industry P/E of 36.60 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Cello World: Consumerware and Writing Instruments Build the Next Leg
Cello World’s roadmap rests on consumerware, writing instruments and glassware sold under the Cello brand, with a wide product range supporting sales.
Revenue grew from Rs 1,375.11 crore in FY22 to Rs 2,378.76 crore in FY26, a 73.0% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit was Rs 331.51 crore. Operating margin was 22.33% in FY26.
Debt to equity is 0.01 and return on equity is 12.27%. FY26 operating cash flow was Rs 255.06 crore against capital expenditure of Rs 219.33 crore. Cello World paid a dividend of Rs 1.5 per share for FY26, a yield of 0.39%. At a P/E of 26.13 against an industry P/E of 45.71, the stock trades below its industry multiple.
What to watch: The P/E of 26.13 against an industry P/E of 45.71 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Branded Medicine Maker, Group Holding Company and Consumerware Stocks in India: GSK Pharma vs Godrej Industries vs Cello World on Key Financials
Among the best branded medicine maker, group holding company and consumerware stocks in India, GSK Pharma leads on FY26 operating margin and return on equity; Godrej Industries leads on FY26 revenue growth and the lowest P/E; Cello World ranks second on FY26 revenue growth and return on equity. The table puts the numbers side by side.
| Metric | GSK Pharma | Godrej Industries | Cello World |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 3,967.03 | 25,980.60 | 2,378.76 |
| FY26 revenue growth | 1.8% | 18.5% | 9.1% |
| FY26 net profit (Rs Cr) | 1,035.98 | 2,411.91 | 331.51 |
| FY26 operating profit margin | 38.60% | 26.91% | 22.33% |
| Return on equity | 45.69% | 11.10% | 12.27% |
| P/E ratio | 40.20 | 15.29 | 26.13 |
| Dividend yield | 2.25% | 0.00% | 0.39% |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Branded Medicine Maker, Group Holding Company and Consumerware Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen branded medicine maker, group holding company and consumerware stocks and shortlist branded medicine maker, group holding company and consumerware stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Branded Medicine Maker, Group Holding Company and Consumerware Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track GSK Pharma, Godrej Industries and Cello World live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare and consumer stocks cover a medicine maker, a holding company and a consumerware brand. GSK Pharma leads on FY26 operating margin and return on equity; Godrej Industries leads on FY26 revenue growth and the lowest P/E; Cello World ranks second on FY26 revenue growth and return on equity.
Across branded medicine maker, group holding company and consumerware stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the branded medicine maker, group holding company and consumerware stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Branded Medicine Maker, Group Holding Company and Consumerware Stocks
Which are the best branded medicine maker, group holding company and consumerware stocks in India with a strong roadmap?
Ans. GlaxoSmithKline Pharmaceuticals, Godrej Industries and Cello World stand out for their roadmaps in a medicine maker, a holding company and a consumerware brand. FY26 revenue growth was 1.8% at GSK Pharma, 18.5% at Godrej Industries and 9.1% at Cello World, and return on equity ranges from 11.10% to 45.69%.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?
Ans. GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P/E of 40.20 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of GSK Pharma, Godrej Industries and Cello World?
Ans. The P/E ratio is 40.20 for GSK Pharma (industry 37.59), 15.29 for Godrej Industries (industry 36.60) and 26.13 for Cello World (industry 45.71). Only GSK Pharma trades at or above the industry multiple.
Which of these branded medicine maker, group holding company and consumerware stocks has the highest return on equity?
Ans. GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by Cello World at 12.27% and Godrej Industries at 11.10%.
What are the risks of investing in branded medicine maker, group holding company and consumerware stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did GSK Pharma, Godrej Industries and Cello World perform in Q1 FY27?
Ans. GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. Godrej Industries reported revenue of Rs 6,360.30 crore, up 11.2% year on year. Cello World reported .
Do branded medicine maker, group holding company and consumerware stocks pay dividends?
Ans. GSK Pharma and Cello World pay dividends. The dividend yield is 2.25% for GSK Pharma and 0.39% for Cello World, based on dividends declared for FY26.
How can I invest in branded medicine maker, group holding company and consumerware stocks in India?
Ans. You can buy branded medicine maker, group holding company and consumerware stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
